NEU 4.38% $1.20 neuren pharmaceuticals limited


  1. 2,085 Posts.
    lightbulb Created with Sketch. 24

    AIC2015: Showcasing Investment Opportunities in Autism Treatment, Assessment & Technology

    Autism Speaks announces preliminary lineup of presenters for 2015 Autism Investment Conference, March 10-11: Showcase Sessions on autism therapeutics, assessment and assistive technology
    February 09, 2015

    About half way down is:

    Larry Glass, chief executive officer of Neuren Pharmaceuticals, will showcase Neuren’s strategy for developing their lead compound, “NNZ-2566,” for the treatment of neurodevelopmental syndromes. Neuren is developing a number of new treatment for brain disorders and conditions, including autism, Rett syndrome and fragile X syndrome.
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Mkt cap $128.8M
Open High Low Value Volume
$1.25 $1.26 $1.20 $85.36K 69.71K

Buyers (Bids)

No. Vol. Price($)
1 2231 $1.20

Sellers (Offers)

Price($) Vol. No.
$1.23 698 1
Last update - 16.10pm 22/10/2018 (20 minute delay) ?
-0.06 ( 3.56 %)
Open High   Low Volume
$1.23 $1.26   $1.22 450
Last updated 14.51pm 22/10/2018 (live) ?
NEU (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.